SuperworthImmucell EPS ICCC
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.08
- Latest quarter, Q2 FY26
- $0.20
- +233% on a year earlier
- Fiscal year 2025
- −$0.11
Immucell's earnings per share was $0.08 over the twelve months to Jun 30, 2026, down 58% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.20, up 233% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.11 | n/a |
| FY2024 | −$0.29 | n/a |
| FY2023 | −$0.75 | n/a |
| FY2022 | −$0.32 | n/a |
| FY2021 | −$0.01 | n/a |
| FY2020 | −$0.14 | n/a |
| FY2019 | −$0.17 | n/a |
| FY2018 | −$0.43 | n/a |
| FY2017 | −$0.04 | −131% |
| FY2016 | $0.13 | −66% |
| FY2015 | $0.38 | n/a |
| FY2014 | −$0.06 | −250% |
| FY2013 | $0.04 | +33% |
| FY2012 | $0.03 | n/a |
| FY2011 | −$0.14 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.20 | +233% | $0.08 | |
| Q1 FY26 | $0.21 | +31% | −$0.06 | |
| Q4 FY25 | −$0.31 | −617% | −$0.11 | |
| Q3 FY25 | −$0.02 | n/a | $0.26 | |
| Q2 FY25 | $0.06 | n/a | $0.19 | |
| Q1 FY25 | $0.16 | n/a | −$0.07 | |
| Q4 FY24 | $0.06 | n/a | −$0.29 | |
| Q3 FY24 | −$0.09 | n/a | −$0.50 | |
| Q2 FY24 | −$0.20 | n/a | −$0.53 | |
| Q1 FY24 | −$0.06 | n/a | −$0.51 | |
| Q4 FY23 | −$0.15 | n/a | −$0.75 | |
| Q3 FY23 | −$0.12 | n/a | −$0.82 |
Against its peers
Companies in Healthcare nearest Immucell's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| NEPHNephros | $0.16 | +33% a year |
| Peer median | $0.41 |
Where Immucell ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Immucell
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.